Detalles de la búsqueda
1.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 2024 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38583093
2.
Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort.
J Am Soc Nephrol
; 35(2): 167-176, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37967469
3.
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Am Heart J
; 271: 38-47, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38401646
4.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
J Am Soc Nephrol
; 34(12): 1965-1975, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37876229
5.
Sex and Gender in Randomized Controlled Trials of Adults Receiving Maintenance Dialysis: A Meta-epidemiologic Study.
Am J Kidney Dis
; 81(5): 575-582.e1, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535536
6.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Am J Kidney Dis
; 82(1): 84-96.e1, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889425
7.
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
Cardiovasc Diabetol
; 22(1): 176, 2023 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37438734
8.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab
; 25(8): 2151-2162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37161691
9.
Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review.
Nephrology (Carlton)
; 28(1): 36-43, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36309984
10.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation
; 143(18): 1735-1749, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554616
11.
GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
Kidney Int
; 101(2): 360-368, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34826514
12.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med
; 380(24): 2295-2306, 2019 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30990260
13.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Am J Kidney Dis
; 79(2): 244-256.e1, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34029680
14.
Digital health and artificial intelligence in kidney research: a report from the 2020 Kidney Disease Clinical Trialists (KDCT) meeting.
Nephrol Dial Transplant
; 37(4): 620-627, 2022 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34791422
15.
Antiplatelet agents for chronic kidney disease.
Cochrane Database Syst Rev
; 2: CD008834, 2022 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35224730
16.
Risk factors for incident kidney disease in older adults: an Australian prospective population-based study.
Intern Med J
; 52(5): 808-817, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33012112
17.
Digital health technologies to support medication adherence in chronic kidney disease.
Nephrology (Carlton)
; 27(12): 917-924, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36176176
18.
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Eur Heart J
; 42(48): 4891-4901, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34423370
19.
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
JAMA
; 327(19): 1888-1898, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35579642
20.
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.
Diabetologia
; 64(11): 2402-2414, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34448033